NanoViricides is trading 10.3% down at $1.34 on September 29, 2026, with no clearly identified catalyst for the intraday decline.

  • The company announced September 28 that dosing began in its Phase II Ebola trial. The news is positive, but available coverage does not connect it to the decline.
  • NanoViricides reported a fiscal fourth-quarter loss of $2.2 million, or $0.10 per share, and said available funding is insufficient for planned objectives through September 30, 2027. Evidence does not establish these disclosures as the cause of the move.